Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GLUE NASDAQ:LIMN NASDAQ:OCGN NASDAQ:TECX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGLUEMonte Rosa Therapeutics$4.81-1.6%$4.97$3.50▼$12.40$302M1.42327,803 shs309,332 shsLIMNLiminatus Pharma$2.00-3.8%$4.64$1.82▼$33.66$54.11MN/A2.60 million shs650,467 shsOCGNOcugen$1.07$1.04$0.52▼$1.29$312.77M4.151.61 million shs1.71 million shsTECXTectonic Therapeutic$17.72-1.7%$21.96$13.70▼$61.07$337.38M3.42452,844 shs331,030 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGLUEMonte Rosa Therapeutics-1.64%-2.63%+8.33%-2.04%-22.67%LIMNLiminatus Pharma-3.85%-25.09%-54.55%+199,999,900.00%+199,999,900.00%OCGNOcugen0.00%+3.88%+3.88%-5.31%-13.01%TECXTectonic Therapeutic-1.72%+5.48%-19.78%-19.05%+1.26%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGLUEMonte Rosa Therapeutics$4.81-1.6%$4.97$3.50▼$12.40$302M1.42327,803 shs309,332 shsLIMNLiminatus Pharma$2.00-3.8%$4.64$1.82▼$33.66$54.11MN/A2.60 million shs650,467 shsOCGNOcugen$1.07$1.04$0.52▼$1.29$312.77M4.151.61 million shs1.71 million shsTECXTectonic Therapeutic$17.72-1.7%$21.96$13.70▼$61.07$337.38M3.42452,844 shs331,030 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGLUEMonte Rosa Therapeutics-1.64%-2.63%+8.33%-2.04%-22.67%LIMNLiminatus Pharma-3.85%-25.09%-54.55%+199,999,900.00%+199,999,900.00%OCGNOcugen0.00%+3.88%+3.88%-5.31%-13.01%TECXTectonic Therapeutic-1.72%+5.48%-19.78%-19.05%+1.26%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGLUEMonte Rosa Therapeutics 2.67Moderate Buy$15.33218.78% UpsideLIMNLiminatus Pharma 0.00N/AN/AN/AOCGNOcugen 3.00Buy$6.00460.75% UpsideTECXTectonic Therapeutic 3.14Buy$80.29353.08% UpsideCurrent Analyst Ratings BreakdownLatest LIMN, GLUE, OCGN, and TECX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025TECXTectonic TherapeuticOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$80.008/4/2025OCGNOcugenChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.007/21/2025TECXTectonic TherapeuticTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$64.006/24/2025OCGNOcugenHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.006/24/2025OCGNOcugenChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGLUEMonte Rosa Therapeutics$75.62M3.93N/AN/A$3.63 per share1.33LIMNLiminatus PharmaN/AN/AN/AN/AN/AN/AOCGNOcugen$4.05M77.22N/AN/A$0.10 per share10.70TECXTectonic TherapeuticN/AN/AN/AN/A$9.54 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGLUEMonte Rosa Therapeutics-$72.70M$0.3613.36N/AN/A13.58%9.95%6.42%11/6/2025 (Estimated)LIMNLiminatus PharmaN/AN/A0.00∞N/AN/AN/AN/AN/AOCGNOcugen-$54.05M-$0.20N/AN/AN/A-1,197.71%-255.25%-86.79%11/13/2025 (Estimated)TECXTectonic Therapeutic-$57.98M-$4.04N/AN/AN/AN/A-30.13%-28.33%11/6/2025 (Estimated)Latest LIMN, GLUE, OCGN, and TECX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025GLUEMonte Rosa Therapeutics-$0.31-$0.15+$0.16-$0.15$7.23 million$23.19 million8/7/2025Q2 2025TECXTectonic Therapeutic-$0.98-$1.07-$0.09-$1.07N/AN/A8/1/2025Q2 2025OCGNOcugen-$0.06-$0.05+$0.01-$0.05$0.35 million$1.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGLUEMonte Rosa TherapeuticsN/AN/AN/AN/AN/ALIMNLiminatus PharmaN/AN/AN/AN/AN/AOCGNOcugenN/AN/AN/AN/AN/ATECXTectonic TherapeuticN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGLUEMonte Rosa TherapeuticsN/A7.167.16LIMNLiminatus PharmaN/AN/AN/AOCGNOcugen9.181.831.83TECXTectonic TherapeuticN/A25.6025.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGLUEMonte Rosa Therapeutics79.96%LIMNLiminatus PharmaN/AOCGNOcugen10.27%TECXTectonic Therapeutic62.63%Insider OwnershipCompanyInsider OwnershipGLUEMonte Rosa Therapeutics6.90%LIMNLiminatus PharmaN/AOCGNOcugen4.42%TECXTectonic Therapeutic38.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGLUEMonte Rosa Therapeutics9061.76 million57.50 millionOptionableLIMNLiminatus PharmaN/A26.01 millionN/AN/AOCGNOcugen80292.30 million279.39 millionOptionableTECXTectonic Therapeutic12018.71 million11.60 millionN/ALIMN, GLUE, OCGN, and TECX HeadlinesRecent News About These CompaniesAdage Capital Partners GP L.L.C. Invests $1.77 Million in Tectonic Therapeutic, Inc. $TECXSeptember 10 at 3:44 AM | marketbeat.comEcoR1 Capital LLC Raises Stock Position in Tectonic Therapeutic, Inc. $TECXSeptember 6, 2025 | marketbeat.comTectonic Therapeutic (NASDAQ:TECX) Now Covered by Analysts at OppenheimerSeptember 6, 2025 | americanbankingnews.comTectonic Therapeutic (NASDAQ:TECX) Coverage Initiated at OppenheimerSeptember 5, 2025 | marketbeat.com132,222 Shares in Tectonic Therapeutic, Inc. $TECX Bought by Ally Bridge Group NY LLCSeptember 5, 2025 | marketbeat.com5AM Venture Management LLC Cuts Holdings in Tectonic Therapeutic, Inc. $TECXSeptember 4, 2025 | marketbeat.comBaker BROS. Advisors LP Invests $1.77 Million in Tectonic Therapeutic, Inc. $TECXSeptember 4, 2025 | marketbeat.comOppenheimer Initiates Coverage of Tectonic Therapeutic (TECX) with Outperform RecommendationSeptember 4, 2025 | msn.com21,126 Shares in Tectonic Therapeutic, Inc. $TECX Acquired by Jump Financial LLCSeptember 4, 2025 | marketbeat.comTectonic Therapeutic initiated with an Outperform at OppenheimerSeptember 3, 2025 | msn.comTectonic Stock Soars Pre-market After Tuesday’s Sell-Off: Oppenheimer Is Hopeful About Company’s Lead CandidateSeptember 3, 2025 | msn.comWellington Management Group LLP Invests $348,000 in Tectonic Therapeutic, Inc. $TECXSeptember 3, 2025 | marketbeat.comTectonic Therapeutic to Participate in September Investor ConferencesAugust 28, 2025 | globenewswire.comTectonic Therapeutic, Inc. (NASDAQ:TECX) Receives Average Recommendation of "Buy" from BrokeragesAugust 24, 2025 | marketbeat.com15,369 Shares in Tectonic Therapeutic, Inc. $TECX Acquired by Cliffwater LLCAugust 20, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Has $614,000 Stock Position in Tectonic Therapeutic, Inc. $TECXAugust 20, 2025 | marketbeat.comTectonic Therapeutic Reports Q2 Financial ResultsAugust 9, 2025 | theglobeandmail.comTectonic (TECX) Q2 R&D Soars 142%August 7, 2025 | fool.comTectonic Therapeutic Announces Second Quarter 2025 Financial Results and Recent Business HighlightsAugust 7, 2025 | manilatimes.netMTectonic Therapeutic, Inc. Added to Russell 3000® Index Following Annual Reconstitution - NasdaqJuly 1, 2025 | nasdaq.comTectonic Therapeutic joins Russell 3000 indexJune 30, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLIMN, GLUE, OCGN, and TECX Company DescriptionsMonte Rosa Therapeutics NASDAQ:GLUE$4.81 -0.08 (-1.64%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$4.82 +0.02 (+0.31%) As of 09/12/2025 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.Liminatus Pharma NASDAQ:LIMN$2.00 -0.08 (-3.85%) As of 09/12/2025 04:00 PM EasternLiminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.Ocugen NASDAQ:OCGN$1.07 0.00 (0.00%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.06 -0.01 (-0.47%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.Tectonic Therapeutic NASDAQ:TECX$17.72 -0.31 (-1.72%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$17.70 -0.02 (-0.14%) As of 09/12/2025 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
